Avidity Biosciences stock surges on expansion of pipeline targeting rare genetic cardiomyopathies and improvements in siRNA ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

State of New Jersey Common Pension Fund D bought a new position in shares of Avidity Biosciences, Inc. (NASDAQ:RNA – Free ...

Barclays analyst Gena Wang maintained a Buy rating on Avidity Biosciences (RNA – Research Report) today and set a price target of $63.00.

In a report released today, Joseph Stringer from Needham maintained a Buy rating on Avidity Biosciences (RNA – Research Report), with a ...

2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class ...

On Friday, Avidity Biosciences Inc (RNA) stock saw a decline, ending the day at $42.18 which represents a decrease of $-7.79 or -15.59% from the prior close of $49.97. The stock opened at $50.32 and ...

Shares of Avidity Biosciences RNA rose more than 12% on Wednesday after the company announced that it is expanding its current RNA-based pipeline of rare muscle disorders to explore a new therapeutic ...

Ratings for Avidity Biosciences (NASDAQ:RNA) were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table summarizes their ...